Close

Drug Research

Chugai Pharmaceutical and GSK Sign Exclusive License Agreement for Anti-Dengue Antibody AID351

Japan-based Chugai Pharmaceutical has entered into an exclusive license agreement with British pharmaceutical company GlaxoSmithKline (GSK) for the anti-dengue virus antibody known as AID351, in a move that advances global efforts to combat one of the world's most widespread...

Advanced Molecular Research Tools Expanding Translational Applications

Clinical research organizations are currently integrating advanced molecular research tools and expanding translational applications to bridge the gap between basic laboratory discovery and patient-centered diagnostics. The transition from bench to bedside requires a suite of technologies that can handle...

Nucleic Acid Testing Workflows Strengthening Molecular Research

Pharmaceutical laboratories are currently standardizing nucleic acid testing workflows, strengthening molecular research to mitigate the risks associated with sample degradation and cross-contamination in high-throughput screening environments. The precision of molecular assays depends entirely on the quality of the starting...

Capsule-in-Capsule Systems Expanding Oral Dosage Design

The pharmaceutical sector has witnessed a growing demand for more sophisticated drug delivery systems that can address the complexities of modern therapeutics. One of the most innovative approaches to meeting this challenge is the development of nested capsule technologies....

Regulatory Intelligence Supporting Accelerated Drug Development

The global pharmaceutical environment is becoming increasingly complex, with regulatory agencies frequently updating guidelines to keep pace with scientific advancements and emerging health threats. In this context, the role of regulatory intelligence supporting accelerated drug development has never been...

Predictive Formulation Design in Oral Solid Dose Development

The integration of computational modeling and algorithmic analysis is currently redefining the methodology behind tablet and capsule creation in the pharmaceutical sector. Pharmaceutical organizations are increasingly transitioning away from empirical trial and error approaches in favor of data driven...

Bristol Myers Squibb Expands Strategic AI Partnership with Schrödinger

Bristol Myers Squibb has expanded its ongoing strategic partnership with Schrödinger through a new agreement to deploy the agentic AI co-scientist platform, Bunsen, across its research operations. Building upon an established collaboration in which Bristol Myers Squibb already utilizes...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »